Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line

Eribulin is a new drug to treat soft tissue sarcoma (STS) that exerts antitumor activity by binding to microtubules. The prognosis of STS is poor, and eribulin is expected to improve the treatment outcome. We observed several cases that exhibited resistance to eribulin and developed an eribulin-resi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Anal Cell Pathol (Amst)
Päätekijät: Yahiro, Kenichiro, Matsumoto, Yoshihiro, Fukushi, Jun-ichi, Kawaguchi, Ken-ichi, Endo, Makoto, Setsu, Nokitaka, IIda, Keiichiro, Fukushima, Suguru, Nakagawa, Makoto, Kimura, Atsushi, Oda, Yoshinao, Nakashima, Yasuharu
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033248/
https://ncbi.nlm.nih.gov/pubmed/30034996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/8987568
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia